RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more
RHYTHM Biosciences Ltd (RHY) - Net Assets
Latest net assets as of December 2025: AU$2.14 Million AUD
Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) has net assets worth AU$2.14 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$3.10 Million) and total liabilities (AU$955.41K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$2.14 Million |
| % of Total Assets | 69.17% |
| Annual Growth Rate | -9.16% |
| 5-Year Change | -61.34% |
| 10-Year Change | N/A |
| Growth Volatility | 198.62 |
RHYTHM Biosciences Ltd - Net Assets Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RHYTHM Biosciences Ltd (2017–2025)
The table below shows the annual net assets of RHYTHM Biosciences Ltd from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$659.89K | -23.90% |
| 2024-06-30 | AU$867.17K | -85.24% |
| 2023-06-30 | AU$5.87 Million | -20.31% |
| 2022-06-30 | AU$7.37 Million | +331.92% |
| 2021-06-30 | AU$1.71 Million | -7.39% |
| 2020-06-30 | AU$1.84 Million | -68.49% |
| 2019-06-30 | AU$5.85 Million | -29.53% |
| 2018-06-30 | AU$8.30 Million | +483.41% |
| 2017-06-30 | AU$1.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RHYTHM Biosciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4243141700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$37.75 Million | 5721.18% |
| Other Comprehensive Income | AU$5.41 Million | 819.81% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$659.89K | 100.00% |
RHYTHM Biosciences Ltd Competitors by Market Cap
The table below lists competitors of RHYTHM Biosciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Generations Bancorp NY Inc
NASDAQ:GBNY
|
$30.65 Million |
|
LOOP INDUSTRIES DL-001
F:3L9
|
$30.66 Million |
|
QES Group Bhd
KLSE:0196
|
$30.66 Million |
|
TUBOS REUNIDOS A EO -02
F:TU1
|
$30.67 Million |
|
Ping Ho Environmental Technology Co., Ltd.
TW:6771
|
$30.63 Million |
|
Econpile Holdings Bhd
KLSE:5253
|
$30.62 Million |
|
Ballston Spa Bancorp Inc
PINK:BSPA
|
$30.61 Million |
|
Heidelberg Pharma AG
F:HPHA
|
$30.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RHYTHM Biosciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 867,166 to 659,892, a change of -207,274 (-23.9%).
- Net loss of 3,829,371 reduced equity.
- Share repurchases of 3,500,050 reduced equity.
- Other comprehensive income increased equity by 316,596.
- Other factors increased equity by 6,805,551.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-3.83 Million | -580.3% |
| Share Repurchases | AU$3.50 Million | -530.4% |
| Other Comprehensive Income | AU$316.60K | +47.98% |
| Other Changes | AU$6.81 Million | +1031.31% |
| Total Change | AU$- | -23.90% |
Book Value vs Market Value Analysis
This analysis compares RHYTHM Biosciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 85.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 17.40x to 85.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | AU$0.01 | AU$0.21 | x |
| 2018-06-30 | AU$0.09 | AU$0.21 | x |
| 2019-06-30 | AU$0.05 | AU$0.21 | x |
| 2020-06-30 | AU$0.02 | AU$0.21 | x |
| 2021-06-30 | AU$0.01 | AU$0.21 | x |
| 2022-06-30 | AU$0.03 | AU$0.21 | x |
| 2023-06-30 | AU$0.03 | AU$0.21 | x |
| 2024-06-30 | AU$0.00 | AU$0.21 | x |
| 2025-06-30 | AU$0.00 | AU$0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RHYTHM Biosciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -580.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -119.97%
- • Asset Turnover: 1.13x
- • Equity Multiplier: 4.29x
- Recent ROE (-580.30%) is below the historical average (-256.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -5.07% | 0.00% | 0.00x | 1.09x | AU$-214.41K |
| 2018 | -21.12% | -2718.67% | 0.01x | 1.02x | AU$-2.58 Million |
| 2019 | -43.52% | -247.67% | 0.17x | 1.06x | AU$-3.13 Million |
| 2020 | -218.28% | -4023.00% | 0.04x | 1.44x | AU$-4.21 Million |
| 2021 | -387.39% | -596.21% | 0.36x | 1.80x | AU$-6.78 Million |
| 2022 | -119.29% | -362.34% | 0.29x | 1.14x | AU$-9.53 Million |
| 2023 | -139.89% | -265.44% | 0.40x | 1.31x | AU$-8.81 Million |
| 2024 | -790.74% | -405.74% | 1.11x | 1.75x | AU$-6.94 Million |
| 2025 | -580.30% | -119.97% | 1.13x | 4.29x | AU$-3.90 Million |
Industry Comparison
This section compares RHYTHM Biosciences Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $159,525,356
- Average return on equity (ROE) among peers: -28.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RHYTHM Biosciences Ltd (RHY) | AU$2.14 Million | -5.07% | 0.45x | $30.64 Million |
| Australian Clinical Labs Ltd (ACL) | $68.99 Million | 59.80% | 4.31x | $217.50 Million |
| Bcal Diagnostics Ltd (BDX) | $6.22 Million | -116.40% | 0.59x | $10.33 Million |
| Capitol Health Ltd (CAJ) | $144.04 Million | 0.60% | 0.82x | $222.66 Million |
| Cryosite Ltd (CTE) | $1.45 Million | 126.98% | 12.60x | $5.03 Million |
| Genetic Signatures Ltd (GSS) | $16.18 Million | -10.68% | 0.02x | $8.20 Million |
| Healius Ltd (HLS) | $1.04 Billion | -62.05% | 1.87x | $208.81 Million |
| Inoviq Ltd (IIQ) | $2.83 Million | -115.42% | 0.16x | $23.33 Million |
| Microba Life Sciences Ltd (MAP) | $32.49 Million | -45.98% | 0.46x | $10.42 Million |
| Monash Ivf Group Ltd (MVF) | $268.44 Million | 9.37% | 0.33x | $116.82 Million |
| Pacific Edge Ltd (PEB) | $13.91 Million | -128.81% | 0.19x | $89.67 Million |